Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, Totten L, Wigg A, Altus R, Colman A, Morales B, Mason S, Jones T, Leembruggen N, Fragomelli V, Sendall C, Guan R, Sutedja D, Tan SS, Dan YY, Lee YM, Luman W, Teo EK, Than YM, Piratvisuth T, Lim SG. Sukeepaisarnjaroen W, et al. Among authors: wigg a. World J Gastroenterol. 2015 Jul 28;21(28):8660-9. doi: 10.3748/wjg.v21.i28.8660. World J Gastroenterol. 2015. PMID: 26229408 Free PMC article.
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
Ramachandran J, Kaambwa B, Muller K, Haridy J, Tse E, Tilley E, Altus R, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd MA, Chinnaratha MA, Harding D, Ralton L, Colman A, Woodman R, Wigg AJ. Ramachandran J, et al. Among authors: wigg aj. Eur J Gastroenterol Hepatol. 2020 Oct;32(10):1381-1389. doi: 10.1097/MEG.0000000000001659. Eur J Gastroenterol Hepatol. 2020. PMID: 31895911
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN). Lubel J, et al. Among authors: wigg a. Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168. Antivir Ther. 2017. PMID: 28422043
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
McCaughan GW, Thwaites PA, Roberts SK, Strasser SI, Mitchell J, Morales B, Mason S, Gow P, Wigg A, Tallis C, Jeffrey G, George J, Thompson AJ, Parker FC, Angus PW; Australian Liver Association Clinical Research Network. McCaughan GW, et al. Among authors: wigg a. Aliment Pharmacol Ther. 2018 Feb;47(3):401-411. doi: 10.1111/apt.14404. Epub 2017 Dec 5. Aliment Pharmacol Ther. 2018. PMID: 29205432
Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation.
Haridy J, Iyngkaran G, Nicoll A, Muller K, Wilson M, Wigg A, Ramachandran J, Nelson R, Bloom S, Sasadeusz J, Watkinson S, Colman A, Altus R, Tilley E, Stewart J, Hebbard G, Liew D, Tse E. Haridy J, et al. Among authors: wigg a. Intern Med J. 2021 Nov;51(11):1927-1934. doi: 10.1111/imj.15037. Epub 2021 Oct 28. Intern Med J. 2021. PMID: 32892478
Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
Haridy J, Wigg A, Muller K, Ramachandran J, Tilley E, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd M, Chinnaratha MA, Harding D, Ralton L, Colman A, Liew D, Iyngkaran G, Tse E; Adelaide Liver Group. Haridy J, et al. Among authors: wigg a. J Viral Hepat. 2018 Nov;25(11):1287-1297. doi: 10.1111/jvh.12943. Epub 2018 Jul 10. J Viral Hepat. 2018. PMID: 29888827
103 results